Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIII.

Autor: Hooimeijer LH; Pediatric Hematology, Beatrix Children's Hospital, Hemophilia Treatment Centre Groningen, 10173University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Stein-Wit MA; Pediatric Hematology, Beatrix Children's Hospital, Hemophilia Treatment Centre Groningen, 10173University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Voskuilen MA; Division of Thrombosis and Hemostasis, Department of Hematology, Hemophilia Treatment Centre Groningen, 10173University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Lukens MV; Laboratory Special Hematology, Department of Laboratory Medicine, Hemophilia Treatment Centre Groningen, 10173University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Meijer K; Division of Thrombosis and Hemostasis, Department of Hematology, Hemophilia Treatment Centre Groningen, 10173University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Mäkelburg AB; Division of Thrombosis and Hemostasis, Department of Hematology, Hemophilia Treatment Centre Groningen, 10173University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands., Tamminga RY; Pediatric Hematology, Beatrix Children's Hospital, Hemophilia Treatment Centre Groningen, 10173University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands.

Publikováno v: Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis [Clin Appl Thromb Hemost] 2023 Jan-Dec; Vol. 29, pp. 10760296231167416.